Evidence map›Paper›PMID 31531672›Full record

ArticleRevista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia2019

[Biliary microbiote in cholecystectomized patients: Review of empirical antibiotherapy].

M Gil Fortuño, L Granel Villach, S Sabater Vidal, R Soria Martín, D Martínez Ramos, J Escrig Sos, R Moreno Muñoz, R Igual Adell

Abstract read
In one paragraph

Article in Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 70% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

M Gil FortuñoMaría Gil Fortuño, Servicio de Microbiología y Parasitología. Hospital General Universitari de Castelló. Avenida de Benicàssim, sn. 12004, Castelló, Spain. gil_marfor@gva.es.
L Granel Villach
S Sabater Vidal
R Soria Martín
D Martínez Ramos
J Escrig Sos
R Moreno Muñoz
R Igual Adell
Hospital General Universitari de Castelló · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveCholecystitis is an important cause of hospital admission. In moderate or severe cholecystitis, the delay in treatment can lead to serious complications. Our objective is to analyze the microorganisms isolated in bile from cholecystectomized patients and their sensitivity pattern, to evaluate the empirical treatment in those cases in which the surgical removal of the gallbladder should be delayed.

methodsProspective descriptive study of biliary cultures of patients undergoing cholecystectomy from May 2013 to February 2015, in the Surgery Department of the Hospital General Universitari de Castelló.

resultsWe studied 196 patients, 83 women (42.3%) and 113 men (57.7%), with an average age of 61.5 years. The most used antibiotics as empiric treatment were piperacillin/tazobactam (77.8%) and amoxicillin/clavulanic (14.8%). In 46.4% of patients (91/196) bile cultures were positive. 165 microorganisms were isolated. The majority were Gram-negative bacilli (60.5%), mainly of the Enterobacterales order (91/54.5%), with Escherichia coli being the most frequent microorganism (24%) followed by Klebsiella spp. (12.5%). 3 E. coli with extended-spectrum beta-lactamase (ESBL) and 1 K. pneumoniae with ESBL were isolated. Microorganisms producing carbapenemase and methicillin-resistant Staphylococcus aureus were not isolated.

conclusionsThe bile microbiota, with a predominance of Enterobacterales is similar to that found in european studies..

Indexed as

CholecystectomyMicrobiotaAdolescentAdultAgedAged, 80 and overAmoxicillin-Potassium Clavulanate CombinationAnti-Bacterial AgentsBileCholecystitisCiprofloxacinEscherichia coliFemaleGram-Negative BacteriaHumansKlebsiellaAmoxicillin-Potassium Clavulanate CombinationAnti-Bacterial AgentsCiprofloxacinMetronidazolePiperacillin, Tazobactam Drug Combination

Identifiers

PMID31531672
PMCPMC6790889
OpenAlexW3004422454

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.